Rare diseases
Investigational molecules
Locations
Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
BelgiumStudy on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer
BelgiumA study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer
FrancePhase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)
FranceStudy of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion
BelgiumPumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation
AustriaPumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%
AustriaA study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer
FranceA study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer
AustriaA study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer
FranceA study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer
GermanyA Study of BNT323 and BNT327 for Patients with Advanced Breast Cancer to Test Safety and Effectiveness
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
